Search results
Results from the WOW.Com Content Network
Lupin's businesses encompass the entire pharmaceutical value chain, ranging from branded and generic formulations, APIs, advanced drug delivery systems to biotechnology. . The company's drugs reach 70 countries [22] with a footprint that covers advanced markets such as USA, Europe, Japan, [23] Australia as well as emerging markets including India, the Philippines and South Africa to name a
Gupta joined Lupin in 1993, [3] and became CEO in 2013. Gupta was the chairman and CEO of Lupin Pharmaceuticals Inc, from 2003 to 2013, and grew the US business from 5% to over 45% of Lupin's total turnover. [2] The US is Lupin's largest market. [citation needed] Lupin's estimated annual cost savings to the US health system is approximately $15 ...
He is the only son of Desh Bandhu Gupta, who founded Lupin in 1968. [3] His eldest sister, Vinita D. Gupta, is the CEO. [citation needed]He has a bachelor's degree in chemical engineering from the University Department of Chemical Technology, Mumbai, and an MBA from the Wharton School, University of Pennsylvania, U.S. in 2002, [3] [1] where he specialized in healthcare, strategic management ...
Austin, Texas; Atlanta, Georgia (metropolitan area); Birmingham, Alabama; Boston, Massachusetts; Charlotte, North Carolina; Chicago, Illinois (metropolitan area ...
For premium support please call: 800-290-4726 more ways to reach us
Alvogen is a private, US-based pharmaceuticals company founded in 2009. Since 2015, it has been majority-owned by CVC Capital Partners and Temasek Holdings. [2] Alvogen focuses on so-called 'difficult-to-make' generic drugs and injectables, and both produces its own products and markets the products of brand name pharmaceutical companies.
Hovione is also present in the inhalation area, and provides a complete range of services, from active pharmaceutical ingredients (APIs), formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corporation (certification) , is a member of Rx-360 [ 1 ] and EFCG.
Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.